KLOW Blend is a four-component research formulation that extends the GLOW combination with KPV, the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. The vial combines GHK-Cu (Copper Tripeptide-1), BPC-157, TB-500, and KPV in a single lyophilized 80mg presentation, commonly formulated at a 50mg / 10mg / 10mg / 10mg ratio. Each of the four components is an independently characterized research peptide, detailed in the component profiles below.
The addition of KPV broadens the blend toward NF-kB and inflammatory-signaling research alongside the tissue-repair, angiogenic, and matrix pathways represented by the other three peptides. KLOW is supplied as a freeze-dried powder for reconstitution and is intended strictly for in vitro and preclinical Research Use Only. It is not for human or veterinary use.
Multi-component blend (see profiles)
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
KLOW has no blend-level publication record; its research basis is the combined literature of its four components. Beyond the GLOW peptides, KPV is studied in preclinical inflammatory-bowel and dermatitis models as the anti-inflammatory C-terminal fragment of alpha-MSH, reported to modulate NF-kB signaling without the pigmentary activity of the parent hormone.
Researchers select KLOW to combine matrix, angiogenic, cytoskeletal, and inflammatory pathways in a single preparation. All reported activity is preclinical and experimental, with no human efficacy conclusions.
KLOW is a market-defined extension of the GLOW blend, adding KPV, a tripeptide first studied for anti-inflammatory activity derived from alpha-MSH, to the GHK-Cu, BPC-157, and TB-500 combination to create a four-peptide research preparation.
Cited literature refers to laboratory and preclinical research. KLOW Blend is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
